What Could FDA Approval Mean For This Global Developer of Innovative Cell-Based Technologies and Therapeutics? Avalon GloboCare Corp. (Nasdaq: AVCO)
Looking at the chart above and doing a little technical analysis you can see the following moving averages:
Daily average price is: $.54 (as of 7/29/22)
50 day moving average at $.49
200 day moving average at $.72
13-day exponential moving average $.49 (first line of resistance)
But what you don’t see – is what this actually means in dollars and cents.
Meaning, that if shares of (AVCO) trend above its first line of resistance at the $.49 range, which they have recently crossed, then sailed through its 50 day moving average of $.49… then the next line of resistance is all the way at $.72, which, if reached, would represent a 41.18% potential move. (as of 7/29/22)
How is this possible?
You see, shares of Avalon GloboCare Corp. (Nasdaq: AVCO) could be at the beginning of what’s called a “Descending Triangle Breakout Strategy.”
…And by definition, the “Descending Triangle Breakout Strategy” as the name suggests, involves the anticipation of a breakout from the descending triangle pattern. (17)
The basic premise of using this strategy is to look at volume once you’ve identified the pattern. You can typically observe that volume begins to diminish toward the end of the descending triangle pattern formation. (17)
It all starts with your body’s T-Cells …
They’re your immune system’s frontline soldiers in the fight against common infections and everyday maladies.
When you’re stuck at home on bedrest, your T-Cells are hard at work getting you back into healthy shape.
Sometimes though, they’re no match for deadly conditions like blood cancer (more specifically leukemia and non-Hodgkins Lymphoma).
That’s where Chimeric Antigen Receptor T-Cell (or “CAR-T”) therapy comes in.4
CAR-T therapy works by extracting your body’s own T-Cells, then genetically modifying them with a receptor that directly attacks specific types of cancers. The cells are then grown and multiplied in the lab before being re-introduced to the body, where they can hunt down cancerous elements in the body’s bloodstream.
That’s why the experts refer to CAR-T therapy as a potential “Living Cure” for some of the world’s deadliest diseases.
Even in its earliest forms as a treatment for blood cancer, this relatively non-invasive treatment leads to lasting remission in no less than 30-40% of patients.
But one company could potentially drive that success rate much higher …
Avalon is a clinical-stage, vertically integrated, leading “CellTech” bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well related diagnostics and therapeutics.
The Company also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets.
Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and other related vaccine and therapeutics.
Their core focus at the moment is their 3rd Generation CAR-T therapy that can potentially be useful in the treatment of cancer and other life-threatening diseases along with their FLASH-CAR technology and stem cell derived Exosome technology called ACTEX. ACTEX can be used to treat a wide variety of conditions, from neurodegenerative disorders to immune health, orthopedic applications, wound management and even weight management.2
Avalon GloboCare successfully filed for a $50 Million shelf offering (S3) in January of 2019, and was also staked a $20 Million credit facility from Chairman Daniel Lu.
That same Daniel Lu also happens to be chairman of the Lu DaoPei hospital group, China’s largest hematology and CAR-T treatment center.3
Those types of connections are key to Avalon GloboCare’s vertical integration:
This kind of integration is a tremendous advantage for companies working in the clinical stage of the process, because it gives Avalon GloboCare a real-world path to market (and to potential revenues) without the imminent need to involve third parties or secure new funding.
That means the company has a direct pipeline that can take compelling research and new ideas, rapidly transform them into a marketable product, and then potentially fast-track the testing process.
Their lead CAR-T candidate, AVA-001, has already completed a pilot first-in-human trial in patients with B-cell acute lymphoblastic leukemia with a stated remission rate far higher than the industry standard.2 Avalon is currently expanding patient recruitment and indication.
Recently, Avalon jointly filed 16 patent applications, and co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology. Patents were filed with the U.S. Patent and Trademark Office (USPTO), the China National Intellectual Property Administration (CNIPA), and under the Patent Cooperation Treaty (PCT) covering 36 countries.
The new intellectual property covers three core patent families:
Engineering and bio-manufacturing of novel CAR T-cells related to the mRNA-based Flash-CARTM cellular therapy platform. This technology has been applied to Avalon’s AVA-011 CAR-T cell therapy candidate, which is currently at the process development stage to generate cGMP-grade CAR-T cells for upcoming first-in-human clinical trials.
Soluble, antibody-like cytokine/chemokine decoy receptors derived from the QTY protein design, with potential applications including mitigation of the “cytokine storm” associated with COVID-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies.
Novel S-layer coated emulsome technology (SLET)-derived fusion proteins intended for mucosal vaccine development, which are designed to trigger robust protective immune responses at the predominant sites of pathogen infection. The SLET platform provides a “molecular GPS system” to guide the trafficking and delivery of a payload to a targeted destination in the body.
Avalon’s headquarters is in Freehold, NJ, and for those who don’t know, New Jersey has one of the hottest breeding grounds for Biotech.
New Jersey’s biotechnology cluster has grown from a mere 30 companies in the early 1990s to approximately 3,200 establishments in the state today, with 46 of those firms responsible for a staggering 70 new FDA drug approvals between 2020 and 2021, according to the trade association BioNJ. And some experts believe that despite recent IPO and capital market challenges, the biotech cluster’s ascension will continue. (14)
Scientific advances and an advantageous New Jersey environment have fueled industry growth. (14)
Avalon’s positioning in New Jersey could prove to be a positive catalyst for growth.
In aggregate, there has been nearly $100 billion of market capitalization from CAR-T companies within recent years. (16)
Ranging from small start-ups to billion-dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide.(16)
Maybe that’s why Avalon insiders are holding tight?
According market research portal Finviz.com, Avalon insiders own over 63% of the company shares as of 7/29/22: (15)
Source 1: https://www.globenewswire.com/news-release/2021/12/17/2354510/0/en/Cancer-Drugs-Market-Size-Worth-Around-US-272-Billion-by-2030.html
Source 2: https://www.youtube.com/watch?v=K2ZnjL0lOM8
Source 3: https://www.youtube.com/watch?v=4zDPUHxzajs
Source 4: https://www.lls.org/sites/default/files/National/USA/Pdf/LLS-CAR-T-cell-Therapy-Timeline.pdf
Source 5: http://www.avalon-globocare.com/
Source 6: https://simplywall.st/stocks/us/healthcare/nasdaq-avco/avalon-globocare
Source 7: https://www.marketwatch.com/press-release/year-end-update-for-this-up-coming-nasdaq-at-the-forefront-of-innovations-in-healthcare-featuring-ai-immunotherapies-avalon-globocare-corp-nasdaqavco-is-avco-the-next-bfri-2022-01-10
Source 8: https://bit.ly/3tZGqcI
Source 9: https://www.proactiveinvestors.com/companies/news/953526/avalon-globocare-says-senlangbio-will-enhance-its-capabilities-in-cell-and-gene-therapy-953526.html
Source 11: https://www.youtube.com/watch?v=IUlflfiMZT0
Source 12: https://finance.yahoo.com/news/avalon-globocare-announces-study-featuring-130000405.html
Source 13: https://finance.yahoo.com/news/avalon-globocare-expands-ip-portfolio-130000830.html
Source 15: https://finviz.com/quote.ashx?t=AVCO
Source 16: https://bioinformant.com/product/car-t-funding-brief/
Source 18: https://stockcharts.com/h-sc/ui?s=AVCO
Source 19: https://www.barchart.com/stocks/quotes/AVCO/price-history/historical
Source 20: https://www.tipranks.com/stocks/avco/insider-trading
This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
(Last updated: 09-29-2023 15:49:06)